LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

LLY

779.27

+0.36%↑

JNJ

152.59

+0.17%↑

ABBV

185.69

+1.88%↑

NVO

69.01

+0.7%↑

UNH

311.78

+0.98%↑

Search

Kura Oncology Inc

Closed

SectorHealthcare

5.76 1.77

Overview

Share price change

24h

Current

Min

5.63

Max

5.87

Key metrics

By Trading Economics

Income

-38M

-57M

Sales

-40M

14M

EPS

-0.66

Profit margin

-407.067

Employees

192

EBITDA

-48M

-65M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+358.55% upside

Dividends

By Dow Jones

Next Earnings

7 Aug 2025

Market Stats

By TradingEconomics

Market Cap

-18M

508M

Previous open

3.99

Previous close

5.76

News Sentiment

By Acuity

50%

50%

164 / 380 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Kura Oncology Inc Chart

Past performance is not a reliable indicator of future results.

Related News

30 Jun 2025, 21:26 UTC

Major Market Movers

AeroVironment Shares Slide on Stock, Notes Offerings

30 Jun 2025, 16:50 UTC

Acquisitions, Mergers, Takeovers

BBVA Won't Withdraw Sabadell Offer

30 Jun 2025, 23:43 UTC

Market Talk

Gold Edges Higher, Underpinned by Fed-Rate Cut Hopes -- Market Talk

30 Jun 2025, 23:38 UTC

Market Talk

Nikkei May Fall as Yen Has Strengthened Amid Trade Uncertainty -- Market Talk

30 Jun 2025, 23:38 UTC

Market Talk

Global Equities Roundup: Market Talk

30 Jun 2025, 23:03 UTC

Earnings

Boeing CFO Exit Is Latest Change in Chief Executive Kelly Ortberg's C-Suite -- Update

30 Jun 2025, 22:50 UTC

Acquisitions, Mergers, Takeovers

Giant Eagle Closes Sale of Its GetGo Business to Alimentation Couche-Tard

30 Jun 2025, 22:50 UTC

Earnings

Boeing Hires Former Lockheed Martin Executive to Succeed CFO Brian West -- Update

30 Jun 2025, 21:26 UTC

Earnings

Berkshire Stock Ends Quarter on Sour Note. It's About Even With S&P 500 So Far in 2025. -- Barrons.com

30 Jun 2025, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

30 Jun 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

30 Jun 2025, 19:46 UTC

Market Talk

Nike's Buzz is Back Amid Lean into Women Sports -- Market Talk

30 Jun 2025, 19:16 UTC

Market Talk

Oil Futures Snap Winning Streak on OPEC+ Outlook -- Market Talk

30 Jun 2025, 19:10 UTC

Market Talk

U.S. Natural Gas Wipes Out Friday's Gains -- Market Talk

30 Jun 2025, 19:07 UTC

Market Talk

Dollar Ends Losing Quarter Facing Downward Pressure -- Market Talk

30 Jun 2025, 18:27 UTC

Market Talk

Gold Has Largest Half-Year Gain Since 2007 -- Market Talk

30 Jun 2025, 17:08 UTC

Acquisitions, Mergers, Takeovers

MicroStrategy Stock Jumps After Latest Bitcoin Purchase as Holdings Near 600,000 Tokens -- Barrons.com

30 Jun 2025, 17:00 UTC

Acquisitions, Mergers, Takeovers

HPE Stock Soars as Juniper Merger Gets Regulatory Approval. There's Just 1 Catch. -- Barrons.com

30 Jun 2025, 16:41 UTC

Market Talk

WTI Crude Undeperforms as U.S.-Canada Trade Talks to Resume -- Market Talk

30 Jun 2025, 16:32 UTC

Market Talk

United Parks' Potential Buyback Resumption Could Be Catalyst For Stock -- Market Talk

30 Jun 2025, 16:23 UTC

Acquisitions, Mergers, Takeovers

BBVA: Offer Remains in Effect in Accordance With Applicable Regulations

30 Jun 2025, 16:22 UTC

Acquisitions, Mergers, Takeovers

BBVA Decided Not to Withdraw Offer for Banco De Sabadell

30 Jun 2025, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

30 Jun 2025, 16:20 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

30 Jun 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

30 Jun 2025, 16:07 UTC

Earnings

Umicore to Post 1H Results on Aug 1

30 Jun 2025, 15:59 UTC

Market Talk

Copper Conditions Set to Remain Tight But Risks Loom -- Market Talk

30 Jun 2025, 15:55 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Home Depot to Consolidate Pro Distribution with GMS Deal -- Market Talk

30 Jun 2025, 15:54 UTC

Market Talk

Gold Futures Recoup Some Losses Though Demand Looks Set to Weaken -- Market Talk

30 Jun 2025, 15:41 UTC

Acquisitions, Mergers, Takeovers

Google Bets Big on Nuclear Fusion With MIT Spinoff Commonwealth -- Barrons.com

Peer Comparison

Price change

Kura Oncology Inc Forecast

Price Target

By TipRanks

358.55% upside

12 Months Forecast

Average 26 USD  358.55%

High 40 USD

Low 8 USD

Based on 13 Wall Street analysts offering 12 month price targets forKura Oncology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

13 ratings

11

Buy

2

Hold

0

Sell

Technical Score

By Trading Central

5.575 / 6.6Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

164 / 380 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.